171610
Anti-Amyloid Precursor Protein, C-Terminal (751-770) Rabbit pAb
liquid, Calbiochem®
別名:
Anti-0443, Anti-APP-CT20
製品名
Anti-Amyloid Precursor Protein, C-Terminal (751-770) Rabbit pAb, liquid, Calbiochem®
biological source
rabbit
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
form
liquid
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Immunoblotting (1:5000-1:20,000)
Immunofluorescence (1:1000)
Immunohistochemistry (1:1000)
Immunoprecipitation (1:1000))
isotype
IgG
shipped in
ambient
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Application
Immunoblotting (1:5000-1:20,000)
Immunofluorescence (1:1000)
Immunohistochemistry (1:1000)
Immunoprecipitation (1:1000)
Immunofluorescence (1:1000)
Immunohistochemistry (1:1000)
Immunoprecipitation (1:1000)
Disclaimer
Toxicity: Standard Handling (A)
General description
Anti-Amyloid Precursor Protein, C-Terminal (751-770), rabbit polyclonal, recognizes full-length APP and C-terminal soluble products CTFα, β, and γ. It is validated for WB, IF, IHC, and IP.
Rabbit polyclonal antibody supplied as undiluted serum. Recognizes full-length APP and C-terminal soluble products CTFγ (~6 kDa), CTFα (~9 kDa), and CTFβ (~11 kDa).
Recognizes full-length APP and C-terminal soluble products CTFγ (~6 kDa), CTFα (~9 kDa), and CTFβ (~11 kDa).Antibody Target Gene Symbol: APP Target Synonym: AAA, AD1, Adap, AL024401, Amyloid precursor, Amyloidogenic glycoprotein, APP isoform 1, APPI, appican, CTFgamma, CVAP, E030013M08RIK, Nexin II, P3, PN2, PreA4, PROTEASE NEXIN2 Entrez Gene Name: amyloid beta (A4) precursor protein Hu Entrez ID: 351 (Related Antibodies: PC729, PC152,PC151, PC150, PC149, NE1012,171609, 171608, 171607, 171606, 171605, 171604, 171603, 171598, 171537) Mu Entrez ID: 11820 Rat Entrez ID: 54226
Immunogen
Human
a synthetic peptide [(C)KMQQNGYENPTYKFFEQMQN] corresponding to amino acids 751-770 of human precursor protein (APP), conjugated to KLH
Legal Information
Purchase of this material is for research use only. Users are invited to request a license from Mayo prior to using the 0433 antibody or any derivatives for clinical diagnostic or therapeutic purposes. For license information, please contact: Mayo Medical Ventures, Office of Technology Commercialization (507) 284-8878, 200 First Street SW, Rochester, MN 55905-001.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Pinnix, I., et al. 2001. J. Biol. Chem.276, 481.
Variables associated with assay conditions will dictate the proper working dilution.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Inderjeet Saluja et al.
Neurobiology of disease, 36(1), 162-168 (2009-07-28)
The neuronal adaptor protein X11alpha/mint-1/APBA-1 binds to the cytoplasmic domain of the amyloid precursor protein (APP) to modulate its trafficking and metabolism. We investigated the consequences of reducing X11alpha in a mouse model of Alzheimer's disease (AD). We crossed hAPPswe/PS-1DeltaE9
Xiqian Lan et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 412-423 (2011-08-10)
Combined antiretroviral therapy (ART) tremendously improved the lifespan and symptoms associated with AIDS-defining illness in affected individuals. However, chronic ART-treated patients frequently develop age-dependent complications, including dementia, diabetes, and hyperlipidemia: all risk factors of Alzheimer's disease. Importantly, the effect of
Ramon Velazquez et al.
Aging cell, 18(6), e13037-e13037 (2019-09-29)
Currently, there are no effective therapies to ameliorate the pathological progression of Alzheimer's disease (AD). Evidence suggests that environmental factors may contribute to AD. Notably, dietary nutrients are suggested to play a key role in mediating mechanisms associated with brain
Ramon Velazquez et al.
Molecular psychiatry, 25(10), 2620-2629 (2019-01-10)
The lack of effective treatments for Alzheimer's disease (AD) is alarming, considering the number of people currently affected by this disorder and the projected increase over the next few decades. Elevated homocysteine (Hcy) levels double the risk of developing AD.
Giselle P Lim et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 25(12), 3032-3040 (2005-03-25)
Epidemiological studies suggest that increased intake of the omega-3 (n-3) polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) is associated with reduced risk of Alzheimer's disease (AD). DHA levels are lower in serum and brains of AD patients, which could result
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| 171610-50ULCN | 07790788048150 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）